Dopaminergic pathway genes influence adverse events related to dopaminergic treatment in Parkinson's disease
ID Redenšek Trampuž, Sara (Author), ID Flisar, Dušan (Author), ID Kojović, Maja (Author), ID Gregorič Kramberger, Milica (Author), ID Georgiev, Dejan (Author), ID Pirtošek, Zvezdan (Author), ID Trošt, Maja (Author), ID Dolžan, Vita (Author)

.pdfPDF - Presentation file, Download (411,70 KB)
MD5: 246813BA2D182D1C823905A0C9DCA187
URLURL - Source URL, Visit https://www.frontiersin.org/articles/10.3389/fphar.2019.00008/full This link opens in a new window

Dopaminergic pathway is the most disrupted pathway in the pathogenesis of Parkinson's disease. Several studies reported associations of dopaminergic genes with the occurrence of adverse events of dopaminergic treatment. However, none of these studies adopted a pathway based approach. The aim of this study was to comprehensively evaluate the influence of selected single nucleotide polymorphisms of key dopaminergic pathway genes on the occurrence of motor and non-motor adverse events of dopaminergic treatment in Parkinson's disease. In total, 231 Parkinson's disease patients were enrolled. Demographic and clinical data were collected. Genotyping was performed for 16 single nucleotide polymorphisms from key dopaminergic pathway genes. Logistic and Cox regression analyses were used for evaluation. Results were adjusted for significant clinical data. We observed that carriers of at least one COMT rs165815 C allele had lower odds for developing visual hallucinations (OR = 0.34; 95% CI = 0.16-0.72; p = 0.004), while carriers of at least one DRD3 rs6280 C allele and CC homozygotes had higher odds for this adverse event (OR = 1.88; 95% CI = 1.00-3.54; p = 0.049 and OR = 3.31; 95% CI = 1.37-8.03; p = 0.008, respectively). Carriers of at least one DDC rs921451 C allele and CT heterozygotes had higher odds for orthostatic hypotension (OR = 1.86; 95% CI = 1.07-3.23; p = 0.028 and OR = 2.30; 95% CI = 1.26-4.20; p = 0.007, respectively). Heterozygotes for DDC rs3837091 and SLC22A1 rs628031 AA carriers also had higher odds for orthostatic hypotension (OR = 1.94; 95% CI = 1.07-3.51; p = 0.028 and OR = 2.57; 95% CI = 1.11-5.95; p = 0.028, respectively). Carriers of the SLC22A1 rs628031 AA genotype had higher odds for peripheral edema and impulse control disorders (OR = 4.00; 95% CI = 1.62-9.88; p = 0.003 and OR = 3.16; 95% CI = 1.03-9.72; p = 0.045, respectively). Finally, heterozygotes for SLC22A1 rs628031 and carriers of at least one SLC22A1 rs628031 A allele had lower odds for dyskinesia (OR = 0.48; 95% CI = 0.24-0.98, p = 0.043 and OR = 0.48; 95% CI = 0.25-0.92; p = 0.027, respectively). Gene-gene interactions, more specifically DDC-COMT, SLC18A2-SV2C, and SLC18A2-SLC6A3, also significantly influenced the occurrence of some adverse events. Additionally, haplotypes of COMT and SLC6A3 were associated with the occurrence of visual hallucinations (AT vs. GC: OR = 0.34; 95% CI = 0.16-0.72; p = 0.005) and orthostatic hypotension (ATG vs. ACG: OR = 2.48; 95% CI: 1.01-6.07; p = 0.047), respectively. Pathway based approach allowed us to identify new potential candidates for predictive biomarkers of adverse events of dopaminergic treatment in Parkinson's disease, which could contribute to treatment personalization.

Keywords:Parkinson's disease, genetic polymorphism, dopaminergic pathway, personalized medicine, adverse events
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Number of pages:10 str.
Numbering:Vol. 10, art. 8
PID:20.500.12556/RUL-128756 This link opens in a new window
ISSN on article:1663-9812
DOI:10.3389/fphar.2019.00008 This link opens in a new window
COBISS.SI-ID:34173401 This link opens in a new window
Publication date in RUL:27.07.2021
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Frontiers in pharmacology
Shortened title:Front Pharmacol
Publisher:Frontiers Media
COBISS.SI-ID:29551833 This link opens in a new window


License:CC BY 4.0, Creative Commons Attribution 4.0 International
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:28.01.2019

Secondary language

Keywords:Parkinsonova bolezen, genetski polimorfizem, dopaminergično zdravljenje, personalizirana medicina, škodljivi dogodki


Funder:ARRS - Slovenian Research Agency
Project number:P1-0170
Name:Molekulski mehanizmi uravnavanja celičnih procesov v povezavi z nekaterimi boleznimi pri človeku

Funder:ARRS - Slovenian Research Agency
Funding programme:Grant for young researchers

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections: